Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
Article number003000
JournalJournal for Immunotherapy of Cancer
Volume9
Issue number8
Number of pages19
ISSN2051-1426
DOIs
Publication statusPublished - 2021
MoE publication typeA1 Journal article-refereed

Fields of Science

  • antibody formation
  • immunotherapy
  • oncolytic virotherapy
  • GAMMA-RS
  • T-CELLS
  • ANTIBODY
  • CANCER
  • NEUTROPHILS
  • RECEPTOR
  • EFFICACY
  • REPLICATION
  • BLOCKADE
  • THERAPY
  • 317 Pharmacy
  • 3122 Cancers
  • 1182 Biochemistry, cell and molecular biology

Cite this